Want to see NVO full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.79Last Year’s EPS
0.93Same Quarter Last Year
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlights very strong commercial and clinical momentum—especially for the Wegovy franchise (oral and high‑dose launches), positive pivotal and Phase II readouts (Etavopivat, UBT251), significant prescription uptake and clear execution on launches and shareholder returns. However, these commercial and R&D successes are balanced by meaningful near‑term financial headwinds: adjusted sales and operating profit declines, margin pressure from lower realized prices, pricing and reimbursement pressures (U.S. and international), guidance implying negative group growth for 2026, and supply/inventory nuances. Overall, product and pipeline momentum is robust, but the company faces material pricing and market access challenges that temper the near‑term financial outlook.Company Guidance
Strong Wegovy pill uptake
Since launch ~16 weeks ago, Wegovy pill generated >2 million total prescriptions and treated >1 million patients; Q1 TRxs were 1.3 million and weekly prescriptions reached ~207,000 (week ending April 17). Close to 80% of Wegovy pill users are GLP-1 treatment‑naive.
Obesity portfolio growth
Obesity care sales increased 22% year-over-year, driven by international and U.S. operations; International Operations obesity sales grew 44% to DKK 9.2 billion while U.S. obesity grew 9%.
Wegovy High‑Dose approval and efficacy
Wegovy 7.2 mg (High‑Dose) approved in the U.S., U.K., EU and Brazil; step‑up trial showed 20.7% mean weight loss when patients adhered to treatment with similar discontinuation due to adverse events versus 2.4 mg.
Commercial momentum and market share
Wegovy franchise leads NBRx market share at ~65%; all three largest PBMs added Wegovy pill at parity on standard formularies by end of Q1; telehealth contributes materially (≈20% of Wegovy sales in some large markets).
Notable clinical and regulatory R&D milestones
Q1 included 6 regulatory approvals and >10 trial initiations; A weekly insulin approved by FDA as first once‑weekly basal for type 2 diabetes; multiple Phase III program initiations (e.g., AMAZE) and planned submissions/decisions across obesity and other indications.
Positive Etavopivat HIBISCUS results in sickle cell disease
Etavopivat met co‑primary endpoints: 27% reduction in annualized VOC rate versus placebo and 48.7% of patients achieved hemoglobin response >1 g/dL at week 24 versus 7.2% with placebo; time to first VOC delayed by ~4 months; regulatory submission planned for Q4 2026.
Promising tri‑agonist (UBT251) Phase II data
In two China Phase II trials, UBT251 showed up to 19.7% mean weight loss at 24 weeks (obesity trial) and up to 2.16 percentage point A1c reduction and 9.8% weight loss (type 2 diabetes trial); global Phase Ib/IIa initiated with Phase II to start Q2 2026.
Strong capital returns and cost transformation progress
Returned nearly DKK 38 billion to shareholders via dividends and buybacks in Q1; invested ~DKK 22 billion in R&D and commercial initiatives; on track to deliver DKK 8 billion of transformation savings and headcount reduced by ~10,000 FTEs versus prior year.
NVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $44.87 | $45.76 | +1.98% |
Feb 04, 2026 | $49.02 | $45.99 | -6.18% |
Nov 05, 2025 | $47.02 | $47.23 | +0.44% |
Aug 06, 2025 | $45.66 | $43.88 | -3.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novo Nordisk (NVO) report earnings?
Novo Nordisk (NVO) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Novo Nordisk (NVO) earnings time?
Novo Nordisk (NVO) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVO EPS forecast?
NVO EPS forecast for the fiscal quarter 2026 (Q2) is 0.79.
